Dasatinib combined with multi-agent chemotherapy regimen in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a prospective study from a single center

• Published in: Zhōnghuá xuèyèxué zázhì 2021-02, Vol.42 (2), p.109-115
• Main Authors: Zhang, G J, Gong, X Y, Qiu, S W, Zhou, C L, Liu, K Q, Lin, D, Liu, B C, Wei, H, Wei, S N, Li, Y, Gu, R X, Gong, B F, Liu, Y T, Fang, Q Y, Mi, Y C, Wang, Y, Wang, J X
• Format: Article
• Language: Chinese
• Subjects: Adult; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Dasatinib - therapeutic use; Hematopoietic Stem Cell Transplantation; Humans; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy; Prospective Studies; Remission Induction; Transplantation, Autologous; Treatment Outcome
• ISSN: 0253-2727
• DOI: 10.3760/cma.j.issn.0253-2727.2021.02.004

This study evaluates the efficacy and safety of dasatinib combined with a multi-agent chemotherapy regimen of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph(+) ALL) patients. This prospective, single-arm, and open clinical study enrolled 30 adult Ph(+) ALL patients who were newly diagnosed and treated from January 2016 to April 2018 in the center of this study. Standard induction chemotherapy was given for 4 weeks. However, dasatinib (100 mg/d) was continuously administered from day 8 until the end of the whole therapy in the induction therapy. Patients who are available for allogeneic or autologous stem cell transplantation (SCT) received transplantation when the disease was evaluated as complete remission. All 30 patients achieved hematological complete remission (HCR) after the induction chemotherapy, and 70.0% (21/30) of them achieved the accumulated molecular complete remission (MCR) . The patients were followed up with a median follow-up time of 37.8 months (32.0-46.6) . The 3 year ov